【摘要】 目的:观察长春瑞宾联合奥沙利铂治疗晚期食管癌的疗效及不良反应。方法:经影像及病理组织学诊断的晚期食管癌28例,静脉滴注奥沙利铂L-OHP135mg/m22h,(d1);静脉注射长春瑞宾25mg/m210min,(d1、d8),21d重复为1周期,所有患者至少接受2个周期的治疗。结果:28例均可评价疗效,总有效率60.71%。初治病例12例,有效率66.67%;复治病例16例。有效率56.25%。在疼痛缓解,全身情况明显改善,生存质量和KPS评分提高等方面均取得了较好的疗效。主要不良反应为骨髓抑制,外周神经毒性,恶心、呕吐等。无治疗相关死亡者。结论:奥沙利铂联合长春瑞宾治疗晚期食管癌缓解率较高,毒性相对较低,值得进一步临床研究。更多还原

【Abstract】 Objective:To observe the efficacy and toxicity of vinorelbin combined with oxaciplain in the patients with advanced esophageal cancer. Methods: Twenty eight advanced esophageal cancer confirmed by maging and pathday findings were enrolled in this study. The chemotherapy was comprised of L-OHP 135mg/m2 infusion for two hours, followed by ten minutes intravenous bolus of vinorelbin 25 mg/ m2, dl,d8,repeated every 21 days. All patients were received at least two cycles of the treatment. Results: The total efficacy rate was 60.71%. The efficacy rate of twelve the first treatment patients was 66.67%. The efficacy rate of sixteen recurrrnt patients was 56.25%. The clinical benifits included pain relief .general influence improvement, quality of life and KPS increase, etc. The major toxicity included peripheral nerve toxicity,nausea,vomiting and so oa No treatment-related death occurred. Conclusion:Oxaliplatin combined with vinorelbin for treatment of advanced esophageal cancer is effective and has mild toxicity. Further clinical investigation should be warranted.更多还原